Scientifically validated Infection Diagnostics with research and data-backed, peer reviewed results
True Bearing, founded in 2017, aims to commercialize research from The St. Laurent Institute and The George Washington University’s Division of Genomic Medicine. The company seeks to launch RNA-based blood tests to lower early disease detection and treatment costs. Currently, True Bearing is developing biomarker panels to improve infection diagnosis.
De-Risked technology achieved –
The Path…
True Bearing Diagnostics is the result of the combined efforts and blending of paths of Dr. Georges St. Laurent, PhD and Tisha Jepson who were looking to make a positive impact in science and in Healthcare in the diagnostics space and Dr. Timothy McCaffrey. Georges and Tisha began by setting up a lab at George Washington University in which we were exploring degenerative diseases through a holistic approach and acknowledging that past and present diagnostic development efforts have often been doomed to failure. The lack of general success in creating pre-symptomatic diagnostics in healthcare supports this observation.
We discovered the cause of this issue in 2006-2007. It is primarily due to flawed target identification technologies, particularly those based on amplification-driven next-generation sequencing (NGS) approaches used then and through today. The large datasets being developed and stored for researchers for diagnostic development have an approximate 30% variance rate, resulting in inaccuracies in disease identification.
Recognizing the limitations of existing technologies, we discovered a more accurate, amplification-free NGS (Next Generation Sequencing) technology. In 2009, we invested $1 million in an instrument, became a non-profit organization, The St. Laurent Institute, and focused on de-risking efforts to improve healthcare.
On a small scale, we supported researchers worldwide with financial and technological aid, allowing them to use this more accurate NGS tool. Our careful investment of about $14 million in non-dilutive funding from 2006 to 2024 has led to significant advancements in diagnostic methods.
We are excited to introduce True Bearing Diagnostics to the healthcare industry after years of planning and risk reduction. Following years of tracking the various researchers we had partially funded, we chose the most advanced and promising of the resulting diagnostics developed. True Bearing has been created as a result of a collaboration between the St. Laurent Institute and George Washington University’s McCaffrey Labs. True Bearing will initially focus on abdominal infections and chronic abdominal pain, allowing for a streamlined path to FDA clearance and commercialization.
This technology has been validated through testing, clinical studies, and patenting, proving its readiness for the infection diagnostics market. Once we secure FDA Clearance, with agreed collaborators including Mayo Clinic, Johns Hopkins University, The University of Virginia, Children’s Hospital Washington, DC, and George Washington, DC, we aim to expand our focus to include a broader range of infections and diagnostic areas.
True Bearing is developing resilient technology that will advance the future of health care across a broad range of diseases, including the significant unmet need for abdominal pain.
True Bearing is committed to offering increased testing accuracy, faster delivery, and significant cost savings for infection diagnosis.
TruNAV
True Bearing Diagnostics has developed TruNAV, a novel RNA-derived blood-based diagnostic test designed to detect infections early.
- TruNAV measures specific RNA transcripts in whole blood associated with activating the human immune system.
- TruNAV RNA transcript targets are susceptible to Neutrophil Activation by any pathogen, be it bacterial, viral, or biofilm-based.
- TruNAV is unique in its ability to detect biofilm infections that cause appendicitis and other conditions.
- TruNAV has undergone multiple studies, resulting in datasets, publications, and patents confirming the approach’s scientific basis.
- TruNAV is poised for a multi-center FDA clinical study to confirm its utility in diagnosing internal infections in patients with abdominal pain.
- TruNAV can also be helpful with future pandemics or infections, like COVID-19 because it can detect the presence of a pathogen even before it is fully identified, sequenced, and treatable.
True Bearing Diagnostics, Inc. (“True Bearing”) is developing TruNAV®, the world’s first highly accurate RNA blood-based diagnostic tool for infection detection. TruNAV will provide a pathogen-agnostic approach to diagnosing infections by identifying the basic type involved—bacterial, viral, or biofilm—and measuring the extent of the infection. This diagnostic tool will enable easy tracking of the effectiveness of therapies, such as antibiotics. Our initial focus will be on diagnosing intra-abdominal infections (IAI).
>90%
Accuracy Rate
$30B
Addressable Market
$5.1B
Abdominal Infection Market
10+
Patents and Publications
CYBIS
In development with George Washington University.
TruCAD
Key statistics about Coronary Artery Disease (CAD)
- In about 50% of cases, a heart attack is the first sign of CAD.
- Over 1 million diagnostic catheterizations are performed annually in the U.S., costing $16 B/yr.
- At least 40% of catheterizations return a “normal” result and, thus, are unnecessary.
- About 9 million myocardial imaging tests are performed yearly in the U.S. at a cost of > $1 billion.
- Roughly 60-70% of imaging tests return a typical result. Thus, they are also unnecessary.
Economics of TruCAD
- The total addressable market is approximately 10 million U.S. adults presenting with symptoms of CAD
- Potential expansion into the “at risk” adult health testing market is 8-10 times greater.
- The market will expand by multiples with worldwide use, especially in countries with limited access to sophisticated cardiac imaging systems.
- Unlike invasive or non-invasive cardiac imaging systems, TruCAD could be employed multiple times throughout a patient’s treatment to monitor the disease process and tailor various therapies.
